A02 – terminated

MYC gene family members as modulators of tumorigenesis and druggable signaling pathways in SCLC

In A02, M. Sos will study the role of MYC paralog activation in SCLC. We will use orthogonal genomic and computational methods to quantify the impact of individual MYC paralogs on the tumorigenesis of SCLC. Furthermore, we will employ CRISPRa/dCas9 based cellular SCLC models and pharmacological perturbation experiments to identify MYC paralog specific vulnerabilities in these tumors.

Principal Investigator

Univ. Prof. Dr. med. Martin L. Sos SFB1399
Univ. Prof. Dr. med. Martin L. Sos

Professor (W2)

University Hospital of Cologne, University of Cologne

Molecular Pathology, Institute for Pathology

Department of Translational Genomics

Curriculum Vitae (CV)